<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260609</url>
  </required_header>
  <id_info>
    <org_study_id>Osiris Protocol 310</org_study_id>
    <nct_id>NCT02260609</nct_id>
  </id_info>
  <brief_title>GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds</brief_title>
  <official_title>A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE® for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and/or Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osiris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osiris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, single-arm study to evaluate the safety and efficacy of
      GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or
      bone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100% granulation of wound as determined by the investigator</measure>
    <time_frame>Up to 16 weeks after the Initial Treatment Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 100% granulation</measure>
    <time_frame>Up to 16 weeks after the Initial Treatment Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of applications of Grafix®</measure>
    <time_frame>Up to 16 weeks after the Initial Treatment Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of percent wound area reduction as determined by the investigator</measure>
    <time_frame>Up to 16 weeks after the Initial Treatment Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Closure of wound defined by 100% re-epithelialization</measure>
    <time_frame>Up to 16 weeks after the Initial Treatment Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Complex Diabetic Foot Wounds</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Grafix®: Cryopreserved Placental Membrane</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grafix®</intervention_name>
    <description>The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.
Patients will be treated for up to 16 weeks.
Patients will be evaluated at screening and then weekly throughout the study or until wound closure.</description>
    <arm_group_label>Open-Label</arm_group_label>
    <other_name>Tissue</other_name>
    <other_name>Allograft Tissue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 18 years and 85 years of age inclusive, as of the date of screening

          2. Confirmed diagnosis of Type I or Type II Diabetes

          3. Index wound graded in the Texas Classification System as Grade II-III, Stage A or C
             (without active infection)

          4. Wound is located on the foot below the malleoli

          5. Wound accommodates up to three (3) 5 cm x 5 cm pieces of GrafixCORE® that completely
             cover the wound

          6. Patient's wound extends through the dermis and into subcutaneous tissue with evidence
             of exposed muscle, tendon, bone, and/or joint capsule

          7. Patient has adequate circulation to the foot as documented by either:

               -  Ankle Brachial Index (ABI) ≥ 0.5 and ≤ 1.2, or

               -  In patients with non-compressible ankle vessels, a Toe BP ≥ 40 mmHg or TcPO2 &gt; 30
                  mmHg, or

               -  Skin perfusion pressure &gt; 30 mmHg

        Exclusion Criteria:

          1. Index Wound is of non-diabetic pathophysiology

          2. Gangrene is present on any part of the affected foot

          3. Index Wound is over a Charcot deformity

          4. The longest dimension of the Index Wound exceeds 15 cm at the Baseline Visit

          5. Patient has a glycated hemoglobin A1 (HbA1c) level of &gt;14%

          6. Requiring intravenous (IV) antibiotics to treat the index wound infection at
             enrollment

          7. Patient has a wound within 15cm of the Index Ulcer identified for study consideration

          8. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or
             cytotoxic agents

          9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune
             Deficiency Syndrome (AIDS)

         10. Current evidence of osteomyelitis, cellulitis, or other evidence of infection
             including fever or pus drainage from the wound site

         11. Patient has active malignancy other than non-melanoma skin cancer

         12. Patient's random blood sugar is &gt;450 mg/dl at screening

         13. Patient has untreated alcohol or substance abuse at the time of screening, or is
             deemed to be non-adherent to the protocol by the Investigator

         14. Pregnant women

         15. Patient is currently enrolled or participated in another investigational device, drug,
             or biological trial within 30 days of screening

         16. Patient has allergy to primary or secondary dressing materials used in this trial

         17. Patient has had within the last 14 days, or is currently undergoing, or is planning
             for wound treatments with enzymes, growth factors, living skin, dermal substitutes or
             other advanced biological therapies

         18. In the opinion of the Investigator, the patient is unsuitable for participation in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carl T. Hayden Medical Research Foundation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complex Wound</keyword>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>DFU</keyword>
  <keyword>GrafixCORE</keyword>
  <keyword>Exposed tendon</keyword>
  <keyword>Exposed bone</keyword>
  <keyword>Allograft tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

